Background {#Sec1}
==========

Over the last decade, there have been nearly one million annual emergency department (ED) visits for acute heart failure (AHF) \[[@CR1]\]. Intravenous loop diuretics are commonly administered to promote diuresis, natriuresis, and congestion relief in these patients \[[@CR2], [@CR3]\]. While diuretics often lead to symptomatic improvement, they have not resulted in decreases in mortality or hospital readmission, and some studies have found that their use in hospitalized patients has been associated with detrimental outcomes \[[@CR4]\].

In AHF, decreased cardiac output leads to arterial underfilling, increased renin-angiotensin-aldosterone system activity, and increased proximal tubule sodium reabsorption \[[@CR5]\]. Retention of sodium and water due to inadequate natriuresis and diuresis are hallmarks of heart failure (HF). Patients with HF have a markedly reduced rate of renal sodium excretion, and cumulative sodium retention has been closely correlated with an increase in body weight \[[@CR6]\]. Loop diuretics are administered to inhibit sodium reabsorption in the thick ascending limb of the loop of Henle and are intended to increase natriuresis. When loop diuretics are effective, the urinary sodium rises and the urinary potassium falls. Poor gut absorption of orally administered loop diuretics, decreased delivery to molecular targets, low serum albumin, renal tubular hypertrophy, and circulating organic acids inhibiting the organic anion transporter all lead to a diminished effect of diuretics, resulting in impaired urinary sodium excretion \[[@CR7]\]. Even when diuretics are given intravenously, diuretic "braking" can be encountered, negating intended natriuresis and contributing to diuretic resistance in patients with AHF. \[[@CR7]\]

Furthermore, a subset of HF patients with a decreased response to diuretic therapy are termed "diuretic resistant" and have a blunted natriuretic response, though the frequency of this phenomenon is not well established \[[@CR7]\]. Inadequate natriuresis and diuresis in patients who develop diuretic resistance have been associated with prolonged hospital lengths of stay and increased mortality \[[@CR8], [@CR9]\]. While clinical characteristics of patients with diuretic resistance have been identified, a reliable prospective measure identifying those who have suboptimal diuretic and natriuretic responsiveness has not been extensively studied \[[@CR10]\]. The inability to predict diuretic responsiveness may delay intensified therapy, thus prolonging hospitalization and delaying decongestion.

Until recently, investigations had focused on defining diuretic and natriuretic responsiveness based on change in body weight or urine output relative to the dose of furosemide administered \[[@CR8], [@CR9], [@CR11], [@CR12]\]. These definitions require up to 96 h to identify diuretic resistance, do not allow a real-time measure of response to diuretic therapy, and have not been conducted in the ED \[[@CR10]\]. Without an early definition of diuretic and natriuretic responsiveness, it is difficult to design prospective ED-based studies of alternative therapies to loop diuretics, such as diuretic combinations, natriuretic doses of mineralocorticoid receptor antagonists, vasoactive medications, and ultrafiltration.

The purpose of the study was not to determine the ideal definition for diuretic resistance but to better understand how the different definitions compare. Definitions generally utilize inexpensive and rapidly available urine electrolytes. The fractional sodium excretion (FeNa) is the percentage of sodium filtered by the kidney and excreted in the urine; it has been used to assess natriuresis in HF patients \[[@CR13]--[@CR15]\]. Baseline FeNa is reduced to less than 1.0% in patients with HF, and a baseline FeNa of less than 0.2% is associated with poor natriuretic response \[[@CR7], [@CR13]--[@CR15]\]. Further, in liver cirrhosis, a condition also associated with poor natriuretic response to diuretics, a natriuresis lower than 50 meq in 8 h after a single intravenous dose of loop diuretics was a predictor of refractory ascites and has been used to define poor natriuretic responsiveness in this population \[[@CR16]\]. An exploratory definition of a urine Na/K ratio \<1.0 was included based on our suspicion that patients with poor natriuretic responsiveness would have disproportionately low ratios of urinary sodium relative to potassium. Understanding the strengths, limitations, and biases of these observations is fundamental to defining diuretic resistance. To better understand these concepts, we directly compared definitions of diuretic resistance in a cohort enrolled in a prospective observational study in ED patients with AHF. A secondary aim was to evaluate hospital length of stay (LOS), 30-day mortality, repeat ED visits, and rehospitalizations for AHF in patients who fulfilled each of the definitions.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

This study was approved by the Vanderbilt University Medical Center Institutional Review Board as exempt from review (IRB\# 150508). Our subjects consisted of a subset of patients with AHF enrolled in a prospective ED cohort study \[[@CR2], [@CR17]\]. Eligible patients received at least one dose of intravenous diuretics and were admitted to the hospital with a diagnosis of AHF. Urine was collected within 12--24 h of their ED visit and analyzed for potassium, sodium, and creatinine. Patients were contacted by telephone and had a medical record review performed to determine 30-day outcomes in the prior cohort study.

Measures of diuretic resistance {#Sec4}
-------------------------------

For our analysis, diuretic resistance was defined using three separate criteria: (1) a baseline FeNa of less than 0.2% \[[@CR7], [@CR13]--[@CR15]\]; (2) a spot urinary sodium of less than 50 meq/L at 12--24-h urine measurement \[[@CR16]\]; and (3) a spot urine Na/K ratio \<1.0.

Statistical analysis {#Sec5}
--------------------

Descriptive statistics, including median and percentages, were used to describe the study population and time of diuretic administration to acquisition of urine. To assess agreement between the definitions of diuretic resistance, we used Cohen's Kappa coefficient and McNemar's test. Wilcoxon rank-sum tests and linear regression were used to assess the association of the biomarkers for diuretic resistance with hospital LOS; Pearson chi-square tests and logistic regression were used to assess the association of the diuretic resistance with AHF-related ED revisits, rehospitalizations for AHF, and mortality within 30 days of the index ED visit. For all regressions, the biomarker was kept continuous and fit with restricted cubic splines (three knots) to relax the linearity assumption.

Results {#Sec6}
=======

Our study included 187 patients (Table [1](#Tab1){ref-type="table"}). Sixty-five percent were male, and the median age was 64 years (interquartile range (IQR) 55, 73). The median systolic blood pressure (SBP) was 149 mmHg (IQR = 130, 178), and 50% were African-American. The median blood urea nitrogen and creatinine in our cohort were 22 mg/dL (IQR = 15, 35) and 1.4 mg/dL (IQR = 1.1, 2.1), respectively. The median b-type natriuretic peptide (BNP) was 1232 pg/mL (IQR = 545, 2198), and 33% had an ejection fraction (EF) greater than 55% on echocardiogram. The median time from diuretic administration to collection of urine for electrolyte measurement was 8.3 h (IQR = 3.0, 12.9).Table 1Descriptive statistics on the entire cohort*N* = 187Median or %Quartiles or frequenciesAge18764(55, 73)Sex187 Female35%(66) Male65%(121)Race187 AA50%(93) Other50%(94)History of renal disease18426%47Home diuretic dose (mg)7760(40, 80)SBP (mmHg)187149(130, 178)BUN18522(15, 35)Serum creatinine (baseline)1871.4(1.1, 2.1)Serum creatinine (12--24 h)1871.5(1.1, 2.2)Urine creatinine (12--24 h)18742(23, 70)eGFR18753(32, 72)BNP (pg/mL)1871232(545, 2198)Urinary sodium (12--24 h)18790(65, 110)Na/K ratio1873.8(1.8, 6.4)Serum sodium (baseline)187140(138, 142)Serum sodium (12--24 h)187139(138, 141)FeNa1872.4(1.0, 5.1)Ejection fraction175 Normal (greater than 55%)33%(57) Mild (45--55%)14%(24) Moderate (25--44%)23%(41) Severe (less than 25%)30%(53)ED lasix/furosemide dose categorized159 ≥80 mg33%(52) \<80 mg67%(107)Hours from diuretic (first of non-initial dose in ED) to lab draw at second visit^c^1328.3(3.0, 12.9)LOS (days)1874(2, 6)Urine output up to second visit1721750(829, 2759)ED revisit for HF187 No86%(161) Yes14%(26)Readmission for HF187 No84%(158) Yes16%(29)Status187 Alive96%(179) Deceased4%(8)^a^Median for continuous variables or percent for dichotomous variables^b^Lower and upper quartile for continuous variables or frequencies^c^Only 132 patients had the time window recorded from diuretic dose to second lab draw

Measures of natriuretic responsiveness {#Sec7}
--------------------------------------

We identified 11 (5.9%) patients with diuretic resistance based on a FeNa of \<0.2% (Additional file [1](#MOESM1){ref-type="media"}). These subjects, compared to those without resistance, had similar ED-measured SBP (142 vs 149 mmHg, respectively, *p* = 0.24) and BNP (894 vs 1249 pg/mL, *p* = 0.14) but were more likely to have better renal function (serum Cr 1.0 vs 1.4 mg/dL, *p* = 0.007). There were 32 (17.1%) patients defined as diuretic resistant based on spot urinary sodium value \<50 meq/L. Using this definition, diuretic resistant and non-diuretic resistant patients had similar ED-measured renal function (serum Cr 1.4 vs 1.4 mg/dL, respectively, *p* = 0.57), SBP (147 vs 149 mmHg, respectively, *p* = 0.79), and BNP levels (1468 vs 1217 pg/mL, *p* = 0.15). Despite approximately one-third of both groups receiving 80 mg or greater of intravenous furosemide, the median urinary output 12--24 h later in those who fulfilled this definition was nearly 900 mL less than those who did not (*p* = 0.005) (Table [2](#Tab2){ref-type="table"}). Twenty (10.7%) patients were diuretic resistant using a urinary Na/K ratio of \<1.0 (Additional file [2](#MOESM2){ref-type="media"}). Patients with and without diuretic resistance based on this definition had similar baseline characteristics, but those of AA race (25 vs 53%, *p* = 0.019) were much less likely to be diuretic resistant.Table 2Descriptive statistics by diuretic resistance assessed using spot urinary sodium cut point of 50 meq/LNumberNormal (*N* = 155)Diuretic resistant (*N* = 32)*p* valueAge18763(54, 73)68(62, 77)0.031Sex1870.62 Female36%5631%10 Male64%9969%22Race1870.0562 AA54%8234%11 Other47%7366%21History of renal disease1840.33 No73%11181%26 Yes27%4119%6Home diuretic dose (mg)7760(40, 80)60(40, 80)0.78SBP187149(130, 178)147(129, 174)0.791BUN18521(15, 35)27(17, 38)0.161Serum creatinine (baseline)1871.4(1.0, 2.0)1.4(1.1, 2.1)0.571Serum creatinine (12--24 h)1871.5(1.1, 2.2)1.4(1.2, 2.1)0.721Urine creatinine (12--24 h)18735(22, 59)75 (46, 124)75 (46, 124)\<0.0011eGFR18753(33, 73)51 (30, 67)51 (30, 67)0.361BNP1871217(532, 2100)1468(864, 2866)0.151Urinary sodium (12--24 h)18799(82, 114)33(23, 41)\<0.0011Na/K ratio1874.5(2.59, 6.79)0.8(0.49, 1.41)\<0.0011Serum sodium (baseline)187140(138, 142)139(138, 140)0.111Serum sodium (12--24 h)187139(138, 141)138(137, 140)0.151FeNa1873.35(1.52, 5.65)0.73(0.18, 1.12)\<0.0011Ejection fraction1750.632 Normal (greater than 55%)31%(45)40%(12) Mild (45--55%)14%(21)10%(3) Moderate (25--44%)23%(33)27%(8) Severe (less than 25%)32%(46)23%(7)ED lasix/furosemide dose categorized1590.822 ≥80 mg32%(43)35%(9) \<80 mg68%(90)65%(17)LOS (days)1873(2, 6)4(3, 7)0.221Urine output up to second visit1721925(1060, 3000)1050(690, 1925)0.0051ED revisit for HF1870.382 No87%(135)81%(26) Yes13%(20)19%(6)Readmission for HF1870.032 No87%(135)72%(23) Yes13%(20)28%(9)Status1870.122 Alive97%(150)91%(29) Deceased3%(5)9%(3)

A comparison between our three definitions of diuretic resistance (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, and [5](#Tab5){ref-type="table"}) found each identified a significantly different (*p* ≤ 0.02) patient cohort. The Kappa for agreement between FeNa and measured urinary sodium was 0.41 (95% CI 0.22--0.6). For FeNa and urine Na/K ratio, the Kappa was 0.62 (95% CI 0.41--0.82). Finally, for urine Na/K ratio and measured urinary sodium concentration, the Kappa was 0.60 (95% CI 0.44--0.77)Table 3Comparison of measured urinary sodium and FeNa as measures of diuretic resistanceMeasured urinary sodiumNormalDiuretic resistantFeNaNormal15422*p* \< 0.001Diuretic resistant110 Table 4Comparison of Na/K ratio and FeNa as measures of diuretic resistanceNa/K ratioNormalDiuretic resistantFeNaNormal16610*p* = 0.02Diuretic resistant110 Table 5Comparison of predicted urinary sodium and measured urinary sodium as measures of diuretic resistanceMeasured urinary sodiumNormalDiuretic resistantNa/K ratioNormal15215*p* = 0.01Diuretic resistant317

Hospital LOS, AHF revisits, AHF readmission, and mortality {#Sec8}
----------------------------------------------------------

There was no difference in hospital LOS, ED revisits or hospital readmissions for AHF, or death between those who did and did not fulfill the definition of diuretic resistance based on FeNa \<0.2%. Patients who were diuretic resistant based on a spot urinary Na \<50 meq/L had a higher rate of hospital readmission for AHF compared to those who were not (28 vs 13%, *p* = 0.03). While diuretic resistance as defined by the dichotomized urinary Na \<50 meq/L failed to show significant associations with LOS, predicted LOS and hospital readmission from the linear regression suggested decreasing LOS and hospital readmission with increasing urinary sodium. (Table [2](#Tab2){ref-type="table"}, Fig. [1a,](#Fig1){ref-type="fig"} [b](#Fig1){ref-type="fig"}). Patients fulfilling the third criterion standard for diuretic resistance, a urine Na/K ratio of \<1, had no differences in LOS, 30-day ED revisit, or hospital readmission for AHF versus those with Na/K ratios of \>1.Fig. 1**a** Spot urinary sodium vs hospital LOS in days. **b** Spot urinary sodium vs likelihood of hospital readmission

Discussion {#Sec9}
==========

We directly compared three definitions of diuretic resistance in 187 ED patients admitted for AHF. Our investigation is the only study to date performed in ED patients after their first dose of diuretic, as other studies focused on inpatients who had received multiple doses of diuretics. Our three definitions of diuretic resistance identified distinctly different patient cohorts, and the prevalence varied widely based on these definitions. Diuretic resistance in our population ranged from 5.9% using FeNa \<0.2 to 17.1% using spot urinary Na \<50 meq/L. This is an important finding as we seek to identify diuretic resistance earlier in a patient's course; the definition utilized would impact the proportion of patients identified. Those who fulfilled a definition of diuretic resistance based on urine Na \<50 meq/L were more likely to have an increased hospital LOS and an increased proportion of AHF readmissions. This has been seen in prior inpatient studies as well \[[@CR9], [@CR18]\].

Traditional definitions have required greater than 24 h to classify patients as diuretic resistant by using change in weight divided by milligram equivalent of loop diuretic \[[@CR9], [@CR19]\]. A formula was recently derived to quantify the relationship between early measures of urinary sodium and 6-h natriuresis \[[@CR10]\]. However, these patients were enrolled a median of 4 days after hospital admission and would not be reflective of the more acute, early diuresis seen in an ED AHF population. The timeframe for definitions we investigated was less than 24 h from ED presentation.

Early identification of ED patients with AHF who will have a suboptimal response to traditional diuretic dosing could help guide therapy and may have implications regarding hospital LOS, readmission, and the cost of care. Those patients identified early in their ED stay as non-responders could be given a higher dose of loop diuretic, a thiazide, aldosterone antagonist, or vasoactive therapy as a means of decongestive therapy. However, other factors need to be considered when evaluating readmission, such as dietary and medication non-adherence. Further, identification of diuretic resistance was not consistent across the investigated definitions, highlighting the importance of developing a standard and objective definition of natriuretic responsiveness.

Our investigation has several limitations. We analyzed a subset of patients from a prospective cohort study performed in the ED. Diuretic dosing was at the discretion of the treating physician and was not standardized; thus, our results could have been influenced by under dosing. In addition, we did not consider other therapies the patient may have received in addition to loop diuretics. Further, the median time from initial ED diuretic dose to the time of urine electrolyte analysis in our study was 8.3 h with an interquartile range of 3--12.9 h. The majority of natriuresis occurs within the first 180 min following parenteral administration of loop diuretics \[[@CR20]\], suggesting the majority of natriuresis may have occurred by the time our urine samples were collected and analyzed. However, many of our patients still had urinary sodium measures consistent with optimal daily natriuresis, suggesting these patients had a brisk and appropriate natriuretic response. Our patients did not have a bladder scan prior to diuretic administration and were not required to have an indwelling urinary catheter placed, nor did the majority receive one as part of routine ED practice; therefore, total urinary output documentation may be less accurate. In addition, if patients did have a urinary catheter placed in the ED, their measured urinary sodium at time of collection could be inaccurate secondary to residual urine in their Foley bag. Because this was a retrospective study, we are unable to classify the severity of the AHF exacerbations in our study. Measurements such as home diuretic dose, time from last diuretic dose, and weight gain compared to dry weight would have added valuable information regarding the extent of baseline disease and the severity of the exacerbation that prompted the patient to seek treatment.

Conclusions {#Sec10}
===========

In conclusion, depending on the definition utilized, the proportion of patients identified as diuretic resistant varies anywhere from 6 to 17.1%. This may impact treatment decisions, especially if changes in therapy are made early in a patient's course based on these definitions, prior to diuretic resistance becoming clinically apparent. The measure most predictive of diuretic resistance in our investigation was urinary sodium \<50 meq/L. These patients may have an increase in hospital readmission for AHF and trends toward a longer inpatient LOS. Measuring urine electrolytes and predicting natriuretic response shortly after initial ED treatment present an opportunity to identify patients who may need intensified therapy early in their hospital course to provide adequate decongestion. These findings need to be explored in a larger cohort of ED patients who receive a standardized initial diuretic regimen, continuous urinary measurements over a 6-h time period, and adjust for other confounders that may contribute to LOS and readmission. This will enable us to quantify natriuresis and predict natriuretic responsiveness via urinary electrolyte patterns, determining the earliest time point during an ED presentation that diuretic resistance can be identified.
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Additional file 1: Table S1.Descriptive statistics by diuretic resistance assessed using a FeNa \<0.2%. (DOC 65 kb) Additional file 2: Table S2.Descriptive statistics by diuretic resistance assessed using a Na/K ratio \< 1. (DOC 64 kb)
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